Twist Bioscience And Biotia Receive Expanded Emergency Use Authorization To Report Genetic Variants Of Sars-Cov-2

Twist Bioscience Corporation, A Company Enabling Customers To Succeed Through Its Offering Of High-Quality Synthetic Dna Using Its Silicon Platform, And Biotia, Inc., A Company That Uses Proprietary Analytical Software For Infectious Disease Diagnostics, Today Received Expanded Emergency Use Authorization (Eua) From The U.S. Food And Drug Administration (Fda) For The Sars-Cov-2 Next-Generation Sequencing (Ngs) Assay For The Qualitative Detection, Identification And Differentiation Of Sars-Cov-2 Lineages And Identification Of Specific Genomic Mutations. The Assay Was Developed In 2020, And This Expanded Authorization Builds On The Initial Eua That Was Received In March 2021 For The Qualitative Detection Of The Sars-Cov-2 Virus.The Hybridization Capture-Based Sars-Cov-2 Ngs Assay Has The Ability To Analyze The Entire Rna Viral Sequence, And To Determine The Presence Or Absence Of The Virus. With The Expanded Authorization, The Reporting Of The Identified And Differentiated Sars-Cov-2 Genetic Mutations And Viral Lineages (E.G. Delta, Omicron) To Clinicians Is Now Authorized, Potentially Aiding Them To Direct Appropriate Clinical Management Based Upon The Specific Lineage Of Virus, When Clinically Indicated.The Authorization Also Allows For The Reporting Of Individual Mutations In Patient Samples, Information That Is Important To Track As The Virus Evolves And New Variants Emerge. The Hybridization Capture-Based Approach Utilized In This Assay Maximizes The Number Of Genetic Variants And Mutations That May Be Identified, Where Other Sequencing Methods May Miss Mutations In Certain Regions.New Mutations In The Sars-Cov-2 Virus Continue To Accumulate And Circulate Around The World, Creating Genetic Variants Of Concern That May Alter Transmissibility Or Vaccine Efficacy, Including The Most Recent Omicron (Ba.2.12.1, Ba.4 And Ba.5) Variants. The Virus Will Continue To Evolve, And We Expect That This Capture-Based Assay Will Serve As An Important New Tool For Viral Identification, Sequencing, And Surveillance. With This Expanded Eua, We Anticipate That These Data Will, For The First Time, Now Enable The Appropriate Treatment Of Covid-19.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!